These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10482591)

  • 1. Role of dendritic cells in the immune response induced by mouse mammary tumor virus superantigen.
    Baribaud F; Maillard I; Vacheron S; Brocker T; Diggelmann H; Acha-Orbea H
    J Virol; 1999 Oct; 73(10):8403-10. PubMed ID: 10482591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus.
    Held W; Waanders GA; MacDonald HR; Acha-Orbea H
    Int Immunol; 1994 Sep; 6(9):1403-7. PubMed ID: 7819149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens.
    Golovkina T; Agafonova Y; Kazansky D; Chervonsky A
    J Immunol; 2001 Feb; 166(4):2244-50. PubMed ID: 11160278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection.
    Vacheron S; Renno T; Acha-Orbea H
    J Virol; 1997 Oct; 71(10):7289-94. PubMed ID: 9311804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen.
    Wrona TJ; Lozano M; Binhazim AA; Dudley JP
    J Virol; 1998 Jun; 72(6):4746-55. PubMed ID: 9573239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early increases in superantigen-specific Foxp3+ regulatory T cells during mouse mammary tumor virus infection.
    Cabrera G; Burzyn D; Mundiñano J; Courreges MC; Camicia G; Lorenzo D; Costa H; Ross SR; Nepomnaschy I; Piazzon I
    J Virol; 2008 Aug; 82(15):7422-31. PubMed ID: 18495774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential infection of immature dendritic cells and B cells by mouse mammary tumor virus.
    Vacheron S; Luther SA; Acha-Orbea H
    J Immunol; 2002 Apr; 168(7):3470-6. PubMed ID: 11907107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B and T cells are required for mouse mammary tumor virus spread within the mammary gland.
    Golovkina TV; Dudley JP; Ross SR
    J Immunol; 1998 Sep; 161(5):2375-82. PubMed ID: 9725233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination.
    Champagne E; Scarpellino L; Lane P; Acha-Orbea H
    Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial stages of mammary tumor virus infection are superantigen independent.
    Pobezinskaya Y; Chervonsky AV; Golovkina TV
    J Immunol; 2004 May; 172(9):5582-7. PubMed ID: 15100301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.
    Krummenacher C; Diggelmann H; Acha-Orbea H
    J Virol; 1996 May; 70(5):3026-31. PubMed ID: 8627779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplays between mouse mammary tumor virus and the cellular and humoral immune response.
    Acha-Orbea H; Finke D; Attinger A; Schmid S; Wehrli N; Vacheron S; Xenarios I; Scarpellino L; Toellner KM; MacLennan IC; Luther SA
    Immunol Rev; 1999 Apr; 168():287-303. PubMed ID: 10399081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
    Maillard I; Erny K; Acha-Orbea H; Diggelmann H
    Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential reactivity of TCR Vbeta10 alleles to a mouse mammary tumor virus superantigen.
    Maillard I; Xenarios I; Diggelmann H; Orbea HA
    Eur J Immunol; 1998 Oct; 28(10):3075-85. PubMed ID: 9808176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells.
    Luther SA; Maillard I; Luthi F; Scarpellino L; Diggelmann H; Acha-Orbea H
    J Immunol; 1997 Sep; 159(6):2807-14. PubMed ID: 9300703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of two infectious mouse mammary tumour viruses: superantigenicity and tumorigenicity.
    Buggiano V; Goldman A; Nepomnaschy I; Bekinschtein P; Berguer P; Lombardi G; Deroche A; Francisco MV; Piazzon I
    Scand J Immunol; 1999 Mar; 49(3):269-77. PubMed ID: 10102644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superantigens and retroviral infection: insights from mouse mammary tumor virus.
    Held W; Acha-Orbea H; MacDonald HR; Waanders GA
    Immunol Today; 1994 Apr; 15(4):184-90. PubMed ID: 8198710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of mouse mammary tumour virus-induced migration of lymphoid cells into lymph nodes.
    Matsuzawa A; Yasuda T; Sakamoto S; Nagase H; Nakano H; Yoshimoto T
    Scand J Immunol; 2001 Jun; 53(6):553-62. PubMed ID: 11422903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to mouse mammary tumor virus in mice lacking the alpha/beta interferon or the gamma interferon receptor.
    Maillard I; Launois P; Xenarios I; Louis JA; Acha-Orbea H; Diggelmann H
    J Virol; 1998 Apr; 72(4):2638-46. PubMed ID: 9525580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.